Last reviewed · How we verify
Psilocybin (Usona Institute)
Psilocybin acts as a serotonin receptor agonist, specifically targeting the 5-HT2A receptor.
Psilocybin acts as a serotonin receptor agonist, specifically targeting the 5-HT2A receptor. Used for Treatment-resistant depression, Anxiety associated with life-threatening diseases.
At a glance
| Generic name | Psilocybin (Usona Institute) |
|---|---|
| Also known as | Magic Mushrooms, Psilocybin, Psychedelic-assisted psychotherapy (PAP) |
| Sponsor | James J. Peters Veterans Affairs Medical Center |
| Target | 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
This activation of the 5-HT2A receptor is thought to contribute to its therapeutic effects, although the exact mechanisms are not fully understood. Research suggests that psilocybin may facilitate changes in brain activity and connectivity, leading to improved mood and reduced symptoms of depression and anxiety.
Approved indications
- Treatment-resistant depression
- Anxiety associated with life-threatening diseases
Common side effects
- Hallucinations
- Nausea
- Dizziness
Key clinical trials
- Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects (PHASE1)
- Anesthesia-Masked Psilocybin Therapy for Major Depression (PHASE2)
- Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability (PHASE1)
- Psilocybin After Trauma Surgery for Pain (PHASE1)
- Psilocybin to Treat Depression in Spinal Cord Injury (PHASE1, PHASE2)
- Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study (PHASE1)
- Investigation to Understand and Optimize Psilocybin (PHASE2)
- Frontline Clinician Psilocybin Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: